Tag: biotechnology industry

May 10, 2018

3D Signatures Strengthens Its Intellectual Property With New Patents Issued for Tests in Alzheimer’s Disease, Hodgkin’s Lymphoma and Multiple Myeloma

3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF), a personalized medicine company with a proprietary software platform (TeloViewTM) based on the three-dimensional analysis of...
April 3, 2018

3D Signatures Inc. Announces Successful Scoring Model Development and Analytical Validation of the Telo-HL(TM) Test for Hodgkin’s Lymphoma

3D Signa­­­­­­tures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is pleased to announce the successful and on-time development of the scoring model for...
March 28, 2018

3D Signatures Collaborates with MDxHealth to Evaluate Telo-PC™ Test in Prostate Cancer

3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF) (the “Company” or "3DS"), a personalized medicine company with a proprietary software platform (TeloViewTM) based on...
March 6, 2018

3D Signatures Inc. and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView™ with Genome Sequence Analysis in Lung Cancer

3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based...
March 1, 2018

3D Signatures Reports Quarter Ended December 31, 2017 Financial Results

3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based...
February 20, 2018

3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL™ Test for Hodgkin’s Lymphoma

3D Signa­­­­­­tures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce that a preliminary third-party analysis of...
December 5, 2017

3D Signatures Inc. Announces the Closing of its Non-Brokered Private Placement

3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS”) is pleased to announce that its previously disclosed non-brokered private...